232 related articles for article (PubMed ID: 36243940)
1. HDAC inhibitors suppress protein poly(ADP-ribosyl)ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: implications for their use in combination with PARP inhibitors and chemotherapeutic drugs.
Valdez BC; Nieto Y; Yuan B; Murray D; Andersson BS
Oncotarget; 2022 Oct; 13():1122-1135. PubMed ID: 36243940
[TBL] [Abstract][Full Text] [Related]
2. Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in pancreatic cancer cells: Implications for novel therapy.
Valdez BC; Tsimberidou AM; Yuan B; Nieto Y; Baysal MA; Chakraborty A; Andersen CR; Andersson BS
Oncotarget; 2024 Jun; 15():361-373. PubMed ID: 38829622
[TBL] [Abstract][Full Text] [Related]
3. Poly(ADP-ribosyl)ation of BRD7 by PARP1 confers resistance to DNA-damaging chemotherapeutic agents.
Hu K; Wu W; Li Y; Lin L; Chen D; Yan H; Xiao X; Chen H; Chen Z; Zhang Y; Xu S; Guo Y; Koeffler HP; Song E; Yin D
EMBO Rep; 2019 May; 20(5):. PubMed ID: 30940648
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin.
Robert C; Nagaria PK; Pawar N; Adewuyi A; Gojo I; Meyers DJ; Cole PA; Rassool FV
Leuk Res; 2016 Jun; 45():14-23. PubMed ID: 27064363
[TBL] [Abstract][Full Text] [Related]
5. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
6. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
7. Poly(ADP-ribosyl)ation of TIMELESS limits DNA replication stress and promotes stalled fork protection.
Rageul J; Lo N; Phi AL; Patel JA; Park JJ; Kim H
Cell Rep; 2024 Mar; 43(3):113845. PubMed ID: 38393943
[TBL] [Abstract][Full Text] [Related]
8. [Poly(ADP-Ribose) Polymerases 1 and 2: Classical Functions and Interaction with New Histone Poly(ADP-Ribosyl)ation Factor HPF1].
Kurgina TA; Lavrik OI
Mol Biol (Mosk); 2023; 57(2):254-268. PubMed ID: 37000654
[TBL] [Abstract][Full Text] [Related]
9. Poly(ADP-ribosyl)ation by PARP1: reaction mechanism and regulatory proteins.
Alemasova EE; Lavrik OI
Nucleic Acids Res; 2019 May; 47(8):3811-3827. PubMed ID: 30799503
[TBL] [Abstract][Full Text] [Related]
10. PARP1 is activated by membrane damage and is involved in membrane repair through poly(ADP-ribosyl)ation.
Mashimo M; Kita M; Nobeyama A; Nomura A; Fujii T
Genes Cells; 2022 Apr; 27(4):305-312. PubMed ID: 35124853
[TBL] [Abstract][Full Text] [Related]
11. Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.
Wiegmans AP; Yap PY; Ward A; Lim YC; Khanna KK
Mol Cancer Ther; 2015 Oct; 14(10):2321-31. PubMed ID: 26294743
[TBL] [Abstract][Full Text] [Related]
12. Poly-ADP ribosylation in DNA damage response and cancer therapy.
Hou WH; Chen SH; Yu X
Mutat Res Rev Mutat Res; 2019; 780():82-91. PubMed ID: 31395352
[TBL] [Abstract][Full Text] [Related]
13. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
Yamaguchi H; Du Y; Nakai K; Ding M; Chang SS; Hsu JL; Yao J; Wei Y; Nie L; Jiao S; Chang WC; Chen CH; Yu Y; Hortobagyi GN; Hung MC
Oncogene; 2018 Jan; 37(2):208-217. PubMed ID: 28925391
[TBL] [Abstract][Full Text] [Related]
14. The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells.
Wilson AJ; Holson E; Wagner F; Zhang YL; Fass DM; Haggarty SJ; Bhaskara S; Hiebert SW; Schreiber SL; Khabele D
Cancer Biol Ther; 2011 Sep; 12(6):484-93. PubMed ID: 21738006
[TBL] [Abstract][Full Text] [Related]
15. New perspectives on the plant PARP family: Arabidopsis PARP3 is inactive, and PARP1 exhibits predominant poly (ADP-ribose) polymerase activity in response to DNA damage.
Gu Z; Pan W; Chen W; Lian Q; Wu Q; Lv Z; Cheng X; Ge X
BMC Plant Biol; 2019 Aug; 19(1):364. PubMed ID: 31426748
[TBL] [Abstract][Full Text] [Related]
16. Mechanistic insight into the role of Poly(ADP-ribosyl)ation in DNA topology modulation and response to DNA damage.
Matkarimov BT; Zharkov DO; Saparbaev MK
Mutagenesis; 2020 Feb; 35(1):107-118. PubMed ID: 31782485
[TBL] [Abstract][Full Text] [Related]
17. Talazoparib enhances the quinacrine-mediated apoptosis in patient-derived oral mucosa CSCs by inhibiting BER pathway through the modulation of GCN5 and P300.
Das C; Dash SR; Sinha S; Paul S; Das B; Bhal S; Sethy C; Kundu CN
Med Oncol; 2023 Nov; 40(12):351. PubMed ID: 37940725
[TBL] [Abstract][Full Text] [Related]
18. DNA maintenance following bleomycin-induced strand breaks does not require poly(ADP-ribosyl)ation activation in Drosophila S2 cells.
Ishak L; Moretton A; Garreau-Balandier I; Lefebvre M; Alziari S; Lachaume P; Morel F; Farge G; Vernet P; Dubessay P
DNA Repair (Amst); 2016 Dec; 48():8-16. PubMed ID: 27793508
[TBL] [Abstract][Full Text] [Related]
19. Poly(ADP-ribose) polymerase inhibitors activate the p53 signaling pathway in neural stem/progenitor cells.
Okuda A; Kurokawa S; Takehashi M; Maeda A; Fukuda K; Kubo Y; Nogusa H; Takatani-Nakase T; Okuda S; Ueda K; Tanaka S
BMC Neurosci; 2017 Jan; 18(1):14. PubMed ID: 28095779
[TBL] [Abstract][Full Text] [Related]
20. Studying PAR-Dependent Chromatin Remodeling to Tackle PARPi Resistance.
Andronikou C; Rottenberg S
Trends Mol Med; 2021 Jul; 27(7):630-642. PubMed ID: 34030964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
